SVCM
IKT icon

Saturn V Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Saturn V Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.85M Buy
3,869,056
+5,611
+0.1% +$10K 1.13% 18
2026
Q1 		$6.49M Buy
3,863,445
+6,646
+0.2% +$11.8K 1.18% 18
2025
Q4 		$7.91M Buy
+3,856,799
New +$6.14M 1.45% 17

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Saturn V Capital Management's IKT Position: Q2 2026 in Review

Saturn V Capital Management increased its Inhibikase Therapeutics (IKT) stake by 0.15% in Q2 2026, buying an estimated $10K and bringing the position to 3,869,056 shares worth $7.85M. The position accounts for 1.13% of the portfolio, ranked #18.

Saturn V Capital Management first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.91M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Saturn V Capital Management held 3,869,056 shares of Inhibikase Therapeutics worth $7.85M as of Q2 2026.
  • Saturn V Capital Management bought 5,611 Inhibikase Therapeutics shares in Q2 2026, an estimated $10K.
  • Inhibikase Therapeutics made up 1.13% of Saturn V Capital Management's portfolio in Q2 2026, its #18 holding.
  • Saturn V Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Saturn V Capital Management's Inhibikase Therapeutics position peaked at $7.91M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.